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Abstract
Platelet Endothelial Aggregation Receptor 1 (PEAR1) is a newly identified membrane pro-
tein reported to be involved in multiple vascular and thrombotic processes. While most stud-
ies to date have focused on the effects of this receptor in platelets, PEAR1 is located in
multiple tissues including the endothelium, where it is most highly expressed. Our first
objective was to evaluate the role of PEAR1 in endothelial function by examining flow-medi-
ated dilation of the brachial artery in 641 participants from the Heredity and Phenotype Inter-
vention Heart Study. Our second objective was to further define the impact of PEAR1 on
cardiovascular disease computationally through meta-analysis of 75,000 microarrays, yield-
ing insights regarding PEAR1 function, and predictions of phenotypes and diseases
affected by PEAR1 dysregulation. Based on the results of this meta-analysis we examined
whether genetic variation in PEAR1 influences endothelial function using an ex vivo assay
of endothelial cell migration. We observed a significant association between rs12041331
and flow-mediated dilation in participants of the Heredity and Phenotype Intervention Heart
Study (P = 0.02). Meta-analysis results revealed that PEAR1 expression is highly correlated
with several genes (e.g. ANG2, ACVRL1, ENG) and phenotypes (e.g. endothelial cell migra-
tion, angiogenesis) that are integral to endothelial function. Functional validation of these
results revealed that PEAR1 rs12041331 is significantly associated with endothelial migra-
tion (P = 0.04). Our results suggest for the first time that genetic variation of PEAR1 is a sig-
nificant determinant of endothelial function through pathways implicated in cardiovascular
disease.
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Introduction
Platelet endothelial aggregation receptor 1 (PEAR1; also known as JEDI and MEGF12) is a
recently identified transmembrane receptor expressed in a number of different tissues, with
highest expression in endothelial cells and megakaryocytes [1]. While little is currently known
regarding the molecular mechanism(s) of this receptor, prior investigations suggest that
PEAR1 is important in a diverse range of biological functions, including sustained platelet
aggregation through glycoprotein αIIbβ3 [2], altered megakaryopoiesis and thrombopoiesis via
PI3K/PTEN pathways [3], and apoptotic neuron clearance through endocytosis-dependent
activities in dorsal root ganglia [4]. In addition to these mechanism-based investigations, sev-
eral studies have examined the role of genetic variation in PEAR1, most notably the intronic
single nucleotide polymorphism (SNP) rs12041331. These studies have implicated rs12041331
genotype in differential PEAR1 expression as well as platelet aggregation, both at baseline and
in the presence of therapeutic agents such as aspirin and prasugrel [5–11]. However, a seem-
ingly paradoxical effect of rs12041331 on cardiovascular phenotypes has been observed; the
allele associated with better aspirin response, as measured by platelet function testing, is also
associated with higher adverse cardiovascular event rates in patients with coronary artery dis-
ease on aspirin, potentially suggesting an alternative role for PEAR1 in cardiovascular disease
progression [10].
Given that PEAR1 is most highly expressed in endothelial cells [1], we first explored the
effects of genetic variation in PEAR1 on endothelial function. Specifically, we tested the impact
of rs12041331 on flow-mediated dilation (FMD) of the brachial artery in 641 participants of
the Heredity and Phenotype Intervention (HAPI) Heart Study. In an attempt to further define
the role of PEAR1 in cardiovascular biology we used a bioinformatics approach called
GAMMA (Global Microarray Meta-Analysis) [12] to identify genes consistently correlated
with PEAR1 expression across 75,000 human 1-color microarray experiments from within the
publicly available datasets in National Center for Biotechnology Information’s Gene Expres-
sion Omnibus. Based on our meta-analysis’s results, we extended our findings by evaluating
and confirming the effect of the PEAR1 rs12041331 variant on endothelial cell migration using
functional ex vivo assays of human umbilical vein endothelial cells (HUVECs) derived from
de-identified umbilical cords.
Materials and Methods
HAPI Heart Study Participants
The HAPI Heart Study recruited 868 healthy Old Order Amish (OOA) participants aged 20
years or older from 2003 to 2006 as previously described [13]. This report evaluates 641 HAPI
Heart Study participants in whom brachial artery FMDmeasurements were recorded. Briefly,
all study participants discontinued the use of medications, vitamins, and supplements 7 days
prior to their initial clinic visit. Physical examinations, anthropometric measures, medical and
family histories, and other phenotype information were collected at the Amish Research Clinic
in Lancaster, Pennsylvania after an overnight fast. Individuals were excluded if any of the fol-
lowing criteria were met: pregnancy, coexisting malignancy, severe hypertension (blood
pressure> 180/105 mmHg), serum creatinine> 2.0 mg/dl, AST or ALT greater than twice the
upper limit of normal, hematocrit< 32%, TSH< 0.4 or> 5.5 mIU/l, or inability to safely dis-
continue prescription and nonprescription medications.
Complete blood count and serum lipid concentrations were assayed by Quest Diagnostics
(Horsham, Pennsylvania), and levels of LDL-cholesterol were calculated using the Friedewald
equation. Any participant with an LDL-cholesterol greater than 160 mg/dl or taking
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prescription cholesterol-lowering medications was designated hyperlipidemic. Individuals
were described as hypertensive if they had one or more of the following criteria: systolic blood
pressure (SBP) 140 mmHg, diastolic blood pressure (DBP) 90 mmHg, or requirement of
prescription blood pressure lowering medications. Diabetes and current smoking status (ciga-
rette, cigar, or pipe) were obtained by self-report.
Study protocols were approved by the Institutional Review Board at the University of Mary-
land School of Medicine, and the study was conducted according to the principles expressed in
the Declaration of Helsinki. Written informed consent was obtained from each HAPI Heart
Study participant; participants were compensated for their participation. Data from the HAPI
Heart Study pertaining to the measurements used for analysis are available upon request to
preserve the anonymity of OOA participants.
Flow-Mediated Dilation (FMD)
Assessment of endothelial function was evaluated by FMD of the brachial artery. All brachial
artery measurements were obtained after an overnight fast. Briefly, the subject’s left arm was
immobilized in the extended position and the left brachial artery was imaged above the antecu-
bital fossa in the longitudinal plane by continuous 2D gray-scale imaging with an 11 MHz
ultrasound (HDI 5000CV [Phillips, Andover, Massachusetts]) by a trained sonographer. A
baseline rest image was acquired and blood flow was estimated by time-averaging the pulsed
Doppler velocity signal obtained from a mid-artery sample volume. Arterial occlusion was cre-
ated by cuff inflation to suprasystolic pressure (50 mmHg above systolic pressure) for 5 min-
utes, after which the cuff was deflated. The longitudinal image of the artery was recorded
continuously from 30 seconds before to 2 minutes after cuff deflation. Flow images were cap-
tured on videotape, and read in a blinded fashion. From longitudinal images, the boundaries
for diameter measurement were identified manually with electronic calipers at the lumen-
intima interface. Five evenly spaced arterial diameter measurements were taken within a 5 cm
segment of vessel at baseline and one minute after cuff deflation, and averaged for the brachial
artery width measurement.
Genotyping
PEAR1 rs12041331 SNP genotyping in HAPI Heart Study participants was performed using a
TaqMan SNP genotyping assay (Applied Biosystems/Life Technologies, Foster City, Califor-
nia). The mean genotype concordance rate for this polymorphism in a subset of duplicate sam-
ples was 100% and the genotype call rate was 98.3%.
GAMMA (Global Microarray Meta-Analysis)
GAMMA [12] was used to identify consistent transcriptional correlations across 75,000 pub-
licly available one-color microarrays from the National Center for Biotechnology Information’s
Gene Expression Omnibus (GEO) database in order to identify a set of 30 genes highly corre-
lated with PEAR1 across a broad range of experimental conditions. Microarrays were quantile-
normalized and processed with an automated quality checking process that includes compari-
son of parametric expression distributions of individual experiments to expected distributions.
Unlike traditional meta-analytic approaches which evaluate gene expression under specific
experimental conditions, and control for cell or tissue type, GAMMA utilizes heterogeneous
conditions in order to identify general co-expression patterns to more accurately identify com-
mon biological responses. In other words, its goal is to identify the strongest gene-gene correla-
tions regardless of experimental condition, tissue, or other variables. Therefore, examination of
PEAR1 co-expression patterns in specific cell types (e.g. endothelial cells) or conditions was
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not explored. The set of genes highly correlated with PEAR1 can then be considered as related
to it in a broad, biological sense and queried for statistically significant biological associations
they may share. This approach is useful for genes with little or no annotation. Because the use
of Gene Ontology for this purpose has fallen under recent criticism [14] and Gene Ontology
covers only biological processes, molecular functions, and cellular components, we also used
literature mining [15] to identify published commonalities for the genes that were most highly
correlated with PEAR1 and had entries in MEDLINE (25 of 30 genes); this includes other cate-
gories such as disease relevance, phenotype, and other genes predicted to be relevant to
PEAR1’s genetic neighborhood. GAMMA’s performance has been previously benchmarked
by predicting Gene Ontology annotations for 5,000 genes and then comparing the predictions
to their known Gene Ontology annotations [12, 16]. Importantly, predicted phenotypes and
functions from GAMMA have also been validated experimentally in several published studies
[16–21].
Cell Culture
Fifty-five de-identified umbilical cords were obtained from the University of Maryland Medical
Center Division of Maternal and Fetal Medicine under an IRB exempt protocol due to their de-
identified nature. Upon receipt of umbilical cords, HUVECs were harvested as described previ-
ously [22]. HUVECS were maintained at 37°C in a 5% CO2 incubator using Endothelial Basal
Media 2 (Lonza, Catalog #CC-3156 & CC-4176, Walkersville, Maryland) containing 2% FBS,
0.04% hydrocortisone, 0.4% hFGF, 0.1% VEGF, 0.1% R3-IGF, 0.1% ascorbic acid, 0.1% hEGF,
0.1% gentamicin-amphotericin-B [GA-1000], and 0.1% heparin. DNA from each cell line was
extracted using a Gentra Puregene Cell Kit (Qiagen, Valencia, California) as recommended by
the manufacturer. PEAR1 rs12041331 genotype was determined using a TaqMan SNP geno-
typing assay (Applied Biosystems/Life Technologies, Foster City, California), which resulted in
the identification of 28 major allele homozygotes (GG), 25 heterozygotes (GA), and 2 minor
allele homozygotes.
Endothelial Cell Migration Assay
We evaluated the impact of PEAR1 rs12041331 genotype on ex vivo endothelial cell migration
using methods described previously [23]. Briefly, 10 primary HUVEC lines were randomly
chosen within each genotype (4 rs12041331 major allele homozygotes [GG], 4 heterozygotes
[GA], and 2 minor allele homozygotes [AA]) and split at passage 3 onto a gelatin-coated 6-well
plate containing Endothelial Basal Media 2. Confluent HUVEC monolayers were scraped in a
uniform manner using a P1000 pipette tip to generate the scratch, which was followed by
replacement of growth media. Cells were photographed at 0 and 6 hours using an Axiocam
MRc 5 camera (Carl Zeiss Microscopy, Pleasanton, California) mounted on a Lumar.V12
microscope (Carl Zeiss Microscopy, Pleasanton, California). The area of the scratch was mea-
sured using ImageJ [24] and used to calculate endothelial cell migration as described in the Sta-
tistical Analysis section.
Statistical Analyses
HAPI Heart Study. Summary statistics and frequencies for the OOA HAPI Heart Study
were calculated using SAS version 9.2 (SAS Institute Inc., Cary, North Carolina). Measures of
Hardy-Weinberg equilibrium were calculated using a χ2 test. For HAPI Heart Study-related
analyses, P-values less than 0.05 were considered statistically significant. All statistical tests
were 2-sided.
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Clinical correlates of FMD response were evaluated using a regression-based approach as
implemented in SOLAR version 4.07 (Texas Biomedical Research Institute, San Antonio,
Texas). Given the unique ancestral history of the Lancaster OOA community, all participants
are related and their relationships were accounted for using the extensive genealogical records
of the OOA [25] by including a polygenic component as a random effect as previously
described [26]. Triglyceride levels were logarithm-transformed for analysis and back-trans-
formed for presentation. The relationship between smoking and FMD was only measured in
sex-stratified analyses to account for the OOA community’s cultural norms that limit smoking
to males. Association analyses with PEAR1 rs12041331 and FMD were performed under an
additive model using a variance component method that assesses the effect of genotype on the
quantitative trait. Analyses were adjusted for age, sex, body mass index (BMI), diabetes, SBP,
DBP, and the aforementioned polygenic component, which was modeled using the relationship
matrix derived from the complete OOA pedigree structure available through the Anabaptist
Genealogy Database [25, 27]. Secondary analyses were adjusted for the same covariates above
in addition to baseline brachial artery width (Dbase) and heart rate (HR) to account for changes
in FMD caused by these variables [28]. Heritability of FMD response corresponds to the pro-
portion of the trait variance accounted for by the polygenic component, and the heritability
estimate was created with adjustments for age and sex.
GAMMA. Statistical analyses implemented by GAMMA have been previously described
[12, 29]. Briefly, 1-color microarrays were processed to create a gene vs experiment expression
matrix in which subsets can be extracted to perform meta-analyses and identify gene-gene cor-
relations. Function, phenotype and disease relevance are predicted by identifying a set of 30
genes that are most correlated in their expression patterns with a query gene of interest. Of
these 30 co-expressed genes, 25 had MEDLINE entries and were analyzed by literature-mining
software [15] for what they have in common (essentially a “guilt by association” approach).
Microarrays were quantile normalized and noise thresholds were used to identify transcription
levels that were statistically significant.
Endothelial Cell Migration. Each of 10 HUVEC lines was plated into 6-well plates, and 3
equidistant photographs were taken per well at 0 and 6 hours after scratch generation of the
endothelial monolayer, resulting in 18 area measurements per cell line at each time point.
Mean endothelial cell migration distance was calculated by dividing the area of the scratch by
the height of the frame. Differences in endothelial cell migration distance between PEAR1
rs12041331 genotype groups were assessed using two-tailed analysis of variance. Genotype-
specific differences in endothelial cell migration distance were assessed 0 and 6 hours post-
scratch generation. P-values< 0.05 were considered statistically significant.
Results
We evaluated the effect of PEAR1 rs12041331 on in vivo endothelial function in 641 subjects of
the HAPI Heart Study. Characteristics of the HAPI Heart Study participants are shown in
Table 1. Subjects were generally healthy, middle-aged (mean age = 43.2 years), drug-naïve, and
had low prevalence of disease (e.g. diabetes [0.78%], hypertension [12.8%], hypercholesterol-
emia [16.9%]), and obesity [mean BMI = 26.3]). FMD was normally distributed in this popula-
tion (S1 Fig). Poorer FMD response was associated with increasing age (0.9% of the variance;
P = 0.007), male sex (17.6% of the variance; P = 3.53 x 10−30), increased Dbase (29.2% of the var-
iance; P = 2.5 x 10−54), increased DBP (0.6% of the variance; P = 0.026), increased SBP (1.5% of
the variance; P = 0.001), decreased HR (7.5% of the variance, P = 2.73 x 10−12), and presence of
hypertension (0.7% of the variance; P = 0.025) (Table 2). Initially, smoking was also signifi-
cantly associated with FMD (1.9% of the variance; P = 1.38 x 10−3), but after stratifying for sex,
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since only men smoke in the Amish community, no association was observed (P = 0.817).
Also, we found that the variance caused by sex was driven by Dbase, as the effect of sex was
diminished (P = 0.85) when adjusting for Dbase. The estimated residual heritability of FMD
after adjustment for age and sex was 0.16 ± 0.09 (P = 0.03).
The minor allele (A) frequency of PEAR1 rs12041331 in the HAPI Heart Study was 0.09,
similar to that reported in other populations of European descent [7, 8, 10], resulting in 535
major allele homozygotes (GG), 101 heterozygotes (GA), and 5 minor allele homozygotes
(AA), and conformed to expectations of Hardy-Weinberg equilibrium (P = 0.92). Characteris-
tics of study participants by rs12041331genotype are shown in S1 Table. In our primary model
accounting for clinical characteristics including age, sex, diabetes, SBP, DBP, and BMI, FMD
was significantly higher in carriers of the PEAR1 rs12041331 A-allele when compared to sub-
jects who did not carry this allele (GG = 10.2 ± 0.3, GA = 10.8 ± 0.6, AA = 16.5 ± 5.4,
P = 0.019). PEAR1 rs12041331 remained significantly associated with FMD after also account-
ing for variation in Dbase (GG = 10.2 ± 0.2, GA = 11.0 ± 0.4, AA = 14.1 ± 2.8, P = 0.032), HR
Table 1. Characteristics of HAPI Heart Study Participants.
Characteristic (Units) Men Women
Number (n) 365 276
Age ± SD (years) 42.2 ± 13.7 44.5 ± 14.1
BMI ± SD (kg/m2) 25.6 ± 3.2 27.3 ± 4.8
Systolic blood pressure ± SD (mm Hg) 122.0 ± 12.8 120.4 ± 16.3
Diastolic blood pressure ± SD (mm Hg) 78.0 ± 8.7 75.4 ± 8.4
No. with hypertension (%)* 42 (11.5) 40 (14.5)
Total cholesterol ± SD (mg/dl) 202.3 ± 44.7 212.7 ± 48.4
LDL cholesterol ± SD (mg/dl) 136.4 ± 40.9 139.6 ± 45.8
HDL cholesterol ± SD (mg/dl) 53.3 ± 13.0 59.0 ± 14.4
Triglycerides ± SD (mg/dl)† 62.8 ± 37.9 70.9 ± 45.5
No. with hypercholesterolemia (%)‡ 57 (15.7) 51 (18.6)
No. with self-reported diabetes (%) 3 (0.8) 2 (0.7)
Hematocrit ± SD (%) 43.2 ± 2.5 38.5 ± 2.5
White blood cell count ± SD (n x 1000) 5.4 ±1.2 5.2 ± 1.0
Platelet count ± SD (n x 100,000) 231.4 ± 52.3 240.8 ± 50.5
No. of current smokers (%)§ 73 (20.2) 0 (0)
No. taking aspirin (%) 14 (3.8) 5 (1.8)
No. taking lipid-lowering medications (%) 5 (1.4) 2 (0.7)
No. taking anti-hypertensive medications (%) 1 (0.3) 0 (0)
Brachial artery width pre-occlusion ± SD (mm) 4.1 ± 0.5 3.1 ± 0.4
Brachial artery width post-occlusion ± SD (mm) 4.4 ± 0.5 3.5 ± 0.4
Abbreviations: BMI, body mass index; HAPI, Heredity and Phenotype Intervention; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD,
standard deviation.
SI conversion factors: To convert HDL-cholesterol, LDL-cholesterol, and total cholesterol values to mmol/L, multiply by 0.0259; triglycerides to mmol/L,
multiply by 0.0113.
*Defined as systolic blood pressure greater than 140 mm Hg or diastolic blood pressure greater than 90 mm Hg or taking prescription medication for
previously diagnosed hypertension.
†Logarithm-transformed for analysis and back-transformed for presentation.
‡Defined as LDL-cholesterol greater than 160 mg/dl or taking prescription medication for previously diagnosed hypercholesterolemia.
§Self-reported history of smoking cigarette, pipe, or cigar. Only men report smoking in the OOA community.
doi:10.1371/journal.pone.0138795.t001
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(GG = 10.2 ± 0.1, GA = 11.1 ± 0.3, AA = 13.7 ± 2.3, P = 0.019), and both Dbase and HR
(GG = 10.2 ± 0.2, GA = 11.0 ± 0.4, AA = 13.9 ± 2.8, P = 0.034).
Using the approach implemented in GAMMA, we identified genes that were most signifi-
cantly associated with PEAR1 expression (S2 Table) and built a genetic neighborhood of pro-
tein-protein interactions shared by the co-expressed genes (Fig 1). Of the 30 most significant
co-expressed gene-pairs, using the 25 with MEDLINE entries, the top phenotypes predicted to
be affected by changes in PEAR1 gene expression were “endothelial cell migration,” “vasculo-
genesis,” and “angiogenesis” (Table 3). Similarly, the disease most highly predicted to be influ-
enced by alterations in PEAR1 gene expression was “vascular disease” (Table 3). Full lists of the
phenotypes and diseases that were predicted to be influenced by PEAR1 expression are shown
in S3 and S4 Tables, respectively.
Given our GAMMA results, we functionally tested whether the well-described PEAR1
rs12041331 variant significantly influenced endothelial cell migration. Genotypic differences in
endothelial cell migration distances were assessed at 6 hours post-scratch generation. Consis-
tent with the results of our microarray meta-analysis regarding endothelial cell migration, we
observed that the A-allele of PEAR1 rs12041331 was significantly associated with increased
endothelial cell migration (P = 0.04; 143.8 ± 58.4 μm for the 4 GG cell lines, 153.1 ± 39.8 μm
for the 4 GA cell lines, and 168.4 ± 34.8 μm for the 2 AA cell lines [Fig 2]). Moreover, this asso-
ciation remained statistically significant when we grouped cells line containing the A-allele (i.e.
GA and AA genotypes) and compared them to GG homozygotes (P = 0.048; 143.8 ± 58.4 μm
for the 4 GG cell lines and 158.2 ± 38.7 μm for cell lines that carried the A-allele [N = 6])
Discussion
PEAR1 was identified in 2005 by Nanda and colleagues as a type I membrane protein that is
highly expressed in platelets and endothelial cells, and is involved in platelet aggregation
through secondary signaling via the αIIbβ3 integrin following platelet-platelet contact [1].
Table 2. Predictors of Variance in Flow-Mediated Dilation in HAPI Study Participants.
Predictor (Units) Beta Standard Error P-value Variance of Significant Predictor (%)
Age (years) -0.05 0.02 0.007 0.9%
Sex (female) 5.07 0.42 3.5 x 10−30 17.6%
BMI (kg/m2) 0.04 0.06 0.448
Current smoking (%)* 0.15 0.66 0.819
Self-reported diabetes (%) -4.72 2.66 0.076
Brachial artery width pre-occlusion (mm) -0.65 0.04 2.5 x 10−54 29.2%
HDL cholesterol (mg/dl) 0.02 0.02 0.369
LDL cholesterol (mg/dl) 0 0.01 0.937
Total cholesterol (mg/dl) 0 0.01 0.578
Triglycerides (mg/dl)
Diastolic blood pressure (mm Hg) -0.06 0.03 0.026 0.6%
Systolic blood pressure (mm Hg) -0.05 0.02 0.001 1.5%
Mean arterial pressure (mm Hg) -0.07 0.02 0.003 1.2%
Heart rate (beats/min) 0.17 0.02 2.7 x 10−12 7.5%
Hypertension (%) -1.54 0.68 0.025 0.7%
rs12041331 genotype (A allele) 1.22 0.62 0.047 0.5%
Abbreviations: BMI, body mass index; HAPI, Heredity and Phenotype Intervention; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*Observed using a sex-stratified analysis to account for the OOA community’s male-only smoking cohort.
doi:10.1371/journal.pone.0138795.t002
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Several subsequent studies, including our own [10], have focused almost exclusively on the
functional or phenotypic effects of this gene in platelets and megakaryocytes [1–3, 5–9, 11].
Taken together, these investigations have yielded insights into the molecular signaling of
PEAR1 as a tyrosine kinase that signals through PI3K and Akt [1, 2], as well as the role of this
receptor in megakaryopoiesis [3], platelet aggregation [1, 2, 5–11], antiplatelet therapy
response [8–11], and cardiovascular events [10].
In this investigation, we measured FMD of the brachial artery, the most widely used nonin-
vasive test of endothelial function, in order to estimate its heritability, establish clinical predic-
tors, and assess the potential effect of genetic variation in PEAR1 on endothelial function in
vivo. In relatively healthy participants of the HAPI Heart Study, we found FMD to be normally
distributed (S1 Fig). Gender and Dbase accounted for over 45% of the variation in FMD, with
age, smoking, SBP, DBP, hypertension, and HR jointly accounting for another 13–14%. Similar
to previous reports [30, 31], our heritability estimates suggest that approximately 16% of the
variation in FMD is attributable to relatedness, for which genetic factors likely contribute. To
our knowledge, this investigation describes the first reported relationship between PEAR1 and
clinical measures of endothelial function. Specifically, our data show that the minor allele of a
common intronic variant (rs12041331) in this gene is significantly associated with greater bra-
chial artery FMD. While the biological mechanism behind this association is not understood
currently, future investigations probing the previously established relationship between PEAR1
and AKT signaling [2], an important mediator of FMD and nitric oxide production, seem
warranted.
Fig 1. PEAR1Genetic Network.Genes highly correlated with PEAR1 (green nodes) were evaluated for
protein-protein interactions (gray nodes) that were shared by at least 2 of the 30 genes analyzed. Green lines
indicate a co-expression relationship; black lines indicate a physical protein-protein interaction. Genetic
neighborhoods of similar pathway or function have been highlighted and labeled.
doi:10.1371/journal.pone.0138795.g001
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Fig 2. The Impact of PEAR1 rs12041331 on Endothelial Cell Migration in Human Umbilical Vein
Endothelial Cells (HUVECs). (A) Representative phase-contrast images of rs12041331-stratified HUVECs
at 0 and 6 hours post-scratch generation during an ex vivo endothelial cell migration assay. Scale bar,
250 μm. (B) Quantitative depiction of mean HUVECmigration. Endothelial cell migration distance was
calculated by dividing the area of the scratch by the height of the frame using ImageJ. Mean endothelial cell
migration distance was calculated based on 72, 72, and 36 independent measurements for GG, GA, and AA
genotypes, respectively, as described in the Materials and Methods section.
doi:10.1371/journal.pone.0138795.g002
Table 3. Meta-Analysis Results of Publicly Available Microarray Datasets.
Top predicted phenotypes # Shared Relations* Score†





Endothelial cell proliferation 9 55
Platelet aggregation 7 55
Cell adhesion 15 52
Top predicted diseases
Vascular disease 12 59
Non-small cell lung carcinoma 14 55
Osteoarthritis 11 46
Preeclampsia 10 42
Pancreatic cancer 12 40
Diabetic nephropathy 9 39
Colorectal cancer 14 39
* Using the 25 genes with MEDLINE entries that are most highly correlated with PEAR1 expression (see
S2 Table), predicted phenotypes, diseases, and genes were identified with Global Microarray Meta-
Analysis (GAMMA), and the number of shared relations represents how many of the 25 genes were related
to term (left column).
†Score reflects the relative enrichment of observed connections within the analyzed network relative to a
random network with the same number of connections per gene, enabling prediction to be prioritized [15].
doi:10.1371/journal.pone.0138795.t003
PEAR1 Influences Endothelial Function
PLOS ONE | DOI:10.1371/journal.pone.0138795 September 25, 2015 9 / 15
In an attempt to gain a more comprehensive view regarding phenotypes and diseases that
may be influenced by PEAR1, we also used in silico genetic and statistical methodologies [12]
to conduct a meta-analysis of publicly available microarray datasets. As expected, our PEAR1
genetic network identified several genes critical in platelet adhesion and aggregation including
vonWillebrand factor (vWF), thrombospondin 1 (THBS1), and plasminogen activator inhibi-
tor 1 (SERPINE1). Interestingly, we also identified several PEAR1 co-expressed genes that are
part of the TGF-β signaling system. These genes are important in blood vessel formation
(ACVRL1) [32], endothelial cell migration and angiogenesis (RhoJ) [33], endothelial cell prolif-
eration, smooth muscle cell recruitment, and vascular remodeling (ENG) [34, 35], as well as
endothelial cell adhesion and survival (CTGF) [36]. Furthermore, several genes that were sig-
nificantly co-expressed with PEAR1 have also been previously implicated in endothelial-related
pathological conditions including pulmonary fibrosis (CTGF) [37] and hemorrhagic telangiec-
tasia (ACVRL1 and ENG) [38]. While, to date, no investigation has evaluated the potential rela-
tionship between PEAR1 and any of these genes and conditions, our results suggest that future
studies may be warranted.
Through GAMMA, we also generated a list of phenotypes that are most likely to be influ-
enced by changes in PEAR1 expression. Interestingly, 6 of the 8 most significantly associated
phenotypes predicted by GAMMA are critical in vascular endothelial function (endothelial cell
migration, vasculogenesis, angiogenesis, neovascularization, endothelial cell proliferation, and
cell adhesion). The two most significantly associated phenotypes that were not related to endo-
thelial function were “platelet aggregation,” which has been previously validated [5–11], and
“lymphangiogenesis,” which, at this time, has never been evaluated in the context of PEAR1.
Similarly, a list of diseases predicted to be influenced by changes in PEAR1 expression was gen-
erated using the same approach. Consistent with our previous report [10], “vascular disease”
was most strongly related to changes in PEAR1 expression. Preeclampsia, a condition charac-
terized by high blood pressure and endothelial dysfunction, was also predicted to be influenced
by PEAR1. Intriguingly, other diseases predicted to be related to PEAR1 included several types
of cancer (e.g. colorectal, pancreatic, and non-small cell lung carcinoma), osteoarthritis, and
diabetic nephropathy. While there is currently no available data suggesting a relationship
between PEAR1 and osteoarthritis, diabetic nephropathy, aortic aneurisms, or cancer risk, it is
interesting to speculate given the role of the TGF-β signaling system in the progression of these
disorders.
In order to experimentally validate, in part, the results of our microarray meta-analysis, we
tested whether a well-described genetic variant in PEAR1 (rs12041331) significantly influenced
endothelial cell migration, the most highly predicted phenotype to be affected by PEAR1 based
on our GAMMA results, through the use of the well-described endothelial cell migration assay.
Indeed, we observed that PEAR1 rs12041331 was significantly associated with endothelial
migration distance. Our results indicate that HUVECs homozygous for the A-allele of PEAR1
rs12041331 have approximately 117% better endothelial cell migration capabilities compared
to cells homozygous for the major allele (G). This novel observation not only strengthens our
confidence in the results obtained by GAMMA, but also provides at least one phenotype by
which PEAR1 influences endothelial cell biology.
To our knowledge, the only other investigation to date that has evaluated PEAR1 in the con-
text of endothelial cell biology was a recently reported publication by Vandenbriele and col-
leagues [39]. In that study, it was observed that lentiviral-mediated knockdown of PEAR1
resulted in enhanced endothelial cell proliferation through the Akt/p21/CDC2 pathway, and,
consistent with the current investigation, observed that PEAR1 knockdown resulted in
increased endothelial cell migration, potentially suggesting that PEAR1 is a negative regulator
of these phenotypes. Given that prior evidence has shown that PEAR1 influences AKT/PTEN
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signaling [2, 39], the increased endothelial migration observed with the rs12041331 minor
allele as well as in PEAR1 knockdown studies could suggest decreased action of PTEN, leading
to an increase in AKT phosphorylation, a key mediator in endothelial cell migration. Given the
observed impact of PEAR1 on endothelial cell proliferation and migration, the authors
extended these findings showing that PEAR1 knockdown also resulted in increased endothelial
tube length, number, and branch points using a matrigel assay. Interestingly, they also showed
that Pear1-/- mice have increased neoangiogenesis compared to wild-type mice using a hind
limb ischemia ligation model as well as significantly decreased wound size and closure time in
an independent skin wound healing model. Importantly, all of these findings are consistent
with the aforementioned top phenotypes predicted to be associated with PEAR1 by GAMMA.
Therefore, the data shown by Vandenbriele and colleagues, combined with our data showing
that genetic variation in PEAR1 influences flow-mediated dilation in humans suggest that
PEAR1 may be a critical determinant of endothelial homeostasis with potential implications in
the development of vascular disease.
Most of the investigations of PEAR1 to date have focused almost exclusively on its role in
platelets and megakaryocytes. Indeed, prior mechanistic investigations by Kauskot and col-
leagues suggest that PEAR1 significantly influences sustained platelet aggregation through gly-
coprotein αIIbβ3 [2] as well as megakaryopoiesis through the PI3K/PTEN pathways [3]. In
addition, several genetic investigations have shown that polymorphisms in PEAR1 are associ-
ated with ex vivo platelet aggregation in response to several platelet agonists (e.g. ADP, colla-
gen, epinephrine) as well as pre- and post-antiplatelet therapy treatment (i.e. aspirin and
prasugrel) [5–11]. In our own previous investigation, we identified PEAR1 rs12041331 as a
strong determinant of collagen-stimulated platelet aggregation after dual anti-platelet therapy
(DAPT) with aspirin and clopidogrel, as well as decreased 1-year survival in DAPT-treated
patients undergoing percutaneous coronary intervention and increased rates of myocardial
infarction (MI) in aspirin-treated patients with stable coronary artery disease [10]. However,
despite the consistent data that shows PEAR1 significantly influences platelet biology and
thrombosis, the current work and the investigation of Vandenbriele and colleagues highlight a
novel genotype-phenotype relationship in the endothelium. Therefore, it is important that
future investigations aiming to understand the relationship between this gene and cardiovascu-
lar disease take into account the pleiotropic nature of PEAR1 in these tissues.
There are some limitations to our study. While the use of FMD is the most commonly used
method to non-invasively assess endothelial function, recent work by Atkinson and Batterham
have shown that inadequate adjustment of FMD analyses, particularly of a ratio-scaling incon-
sistency between percent FMD and baseline vessel diameter, leads to biased results [40]. In
order to minimize the effect of this potential confounder and others, we tested for association
between PEAR1 rs12041331 and FMD using several statistical models that adjusted for differ-
ent clinical variables that impact FMDmeasurements (e.g. age, sex, Dbase, and HR). In all mod-
els, PEAR1 rs12041331 remained significantly associated with FMD. In addition, given the
number of minor allele homozygotes (N = 5) and observed genotypic means, we also tested for
association between rs12041331 and FMD using both dominant (GG vs AG/AA; P = 0.03) and
recessive (GG/AG vs AA; P = 0.05) genetic models, showing a consistent direction of associa-
tion. A potential limitation of the approach implemented in GAMMA is that it tends to be
biased towards inclusion of genes that change significantly in their expression level and against
genes whose transcriptional levels are too low to reliably detect. Although the analysis we per-
formed of multiple genes for their published commonalities tends to reduce the bias towards a
small number of genes skewing the results, the scientific literature itself may have its own biases
in terms of preferences for what is both studied and reported. Therefore, while we functionally
validated one phenotype predicted by GAMMA (i.e. endothelial migration), we believe future
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functional experiments to evaluate the relationship between PEAR1 and the genes/phenotypes
identified by GAMMA are warranted.
The dynamic relationship between platelets and endothelial cells is critical in cardiovascular
physiology, and dysfunction of either cell type can lead to a cardiovascular event. There is a
growing body of literature indicating that PEAR1 has important effects on platelet-related pro-
cesses and cardiovascular outcomes. In this investigation, we have established for the first time
that genetic variation in PEAR1 significantly impacts endothelial function as well. Looking for-
ward, it is critical to further characterize the function(s) of PEAR1 in both platelet and endo-
thelial cells to elucidate the mechanism by which this gene may contribute to cardiovascular
risk. Once understood, PEAR1 may be a novel target for treatment and prevention of cardio-
vascular disease.
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